{"title":"Weight Loss","description":"\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"font-family: 'Arial',sans-serif;\"\u003eThis collection brings together the best peptides for fat loss research available in our Canadian catalog — compounds with documented preclinical activity on adiposity, lipolysis, and metabolic regulation. Each peptide for fat loss research design in this collection operates through a distinct molecular mechanism.\u003c\/span\u003e\u003c\/p\u003e","products":[{"product_id":"buy-retatrutide-canada","title":"GLP-3 (Retatrutide)","description":"\u003ch2\u003e\u003cb\u003eBuy Retatrutide in Canada — Triple-Agonist Research Peptide\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuy Retatrutide in Canada as a research-grade triple receptor agonist for metabolic, glycemic, and adiposity research designs. Retatrutide (LY3437943) is an investigational triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, with Phase 2 clinical data published in 2023 showing dose-dependent body weight reductions and HbA1c improvements. The compound combines balanced agonist activity across all three target receptors with structural modifications — Aib substitutions and C20 fatty diacid acylation — that extend half-life through albumin binding. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e Available on batch-specific COA\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 2381089-83-2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes Retatrutide a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eRetatrutide is the only compound in advanced clinical investigation that simultaneously activates the GLP-1, GIP, and glucagon receptors. Earlier incretin peptides target one or two; the addition of glucagon-receptor agonism reintroduces a hepatic and energy-expenditure dimension that mono- and dual-agonists cannot address.\u003c\/p\u003e\n\u003cp\u003eDeveloped at Eli Lilly and disclosed in 2022 under the code LY3437943, retatrutide carries Aib substitutions for DPP-4 resistance and a C20 fatty diacid for albumin binding and extended circulation. Phase 2 trial data published in 2023 in major peer-reviewed medical journals reported dose-dependent changes in body weight and HbA1c, making it a reference tool compound for researchers comparing the contributions of each receptor pathway.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eGlycemic Regulation —\u003c\/b\u003e Phase 2 trial data published in 2023 reported dose-dependent reductions in HbA1c in study populations with type 2 diabetes, supporting investigation into the contribution of triple-receptor activation to glucose handling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAdiposity \u0026amp; Body Composition —\u003c\/b\u003e Animal and clinical trial datasets describe substantial reductions in fat mass over 24- and 48-week protocols, with investigators attributing the magnitude to combined incretin and glucagon-receptor effects on intake and expenditure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eHepatic Lipid Metabolism —\u003c\/b\u003e Researchers studying NAFLD and MASH models have examined retatrutide's effect on hepatic triglyceride content, where glucagon-receptor agonism is hypothesized to drive intrahepatic lipid mobilization beyond what GLP-1 alone produces.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnergy Expenditure —\u003c\/b\u003e Preclinical work in rodent models has reported elevations in resting energy expenditure attributed to the glucagon receptor component, distinguishing retatrutide from GLP-1 monotherapy in mechanistic dissection studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCardiometabolic Markers —\u003c\/b\u003e Secondary endpoints in published trials have included blood pressure, lipid panel, and inflammatory markers, giving researchers additional data points for modeling broader cardiometabolic effects of triple agonism.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with retatrutide often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-tesamorelin-canada\" title=\"View Tesamorelin Product Page\"\u003eTesamorelin\u003c\/a\u003e\u003c\/b\u003e — GH-axis analog studied in visceral adiposity and lipid metabolism research; useful mechanistic contrast to incretin-driven fat mass effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-mots-c-canada\" title=\"View MOTS-c Product Page\"\u003eMOTS-c\u003c\/a\u003e\u003c\/b\u003e — Mitochondria-derived peptide investigated for insulin sensitivity and exercise-mimetic activity; complements retatrutide's receptor-level metabolic effects with a cellular-energetics angle.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/nad-plus\" title=\"View NAD+ Product Page\"\u003eNAD+\u003c\/a\u003e\u003c\/b\u003e — Mitochondrial cofactor studied alongside metabolic peptides in cardiometabolic and longevity research designs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\n\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003cb\u003e\u003c\/b\u003e\n\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eHow is retatrutide different from tirzepatide or semaglutide?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eSemaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1\/GIP agonist. Retatrutide adds a third arm — glucagon receptor agonism — which preclinical and Phase 2 data suggest contributes additional hepatic lipid mobilization and energy expenditure effects not observed with mono- or dual-agonist compounds.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for retatrutide?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePhase 2 trials in obesity and type 2 diabetes have been completed and published in major peer-reviewed medical journals, including data on body weight, glycemic markers, and tolerability. Phase 3 development is ongoing under Eli Lilly's TRIUMPH program. The preclinical literature spans metabolic, hepatic, and energy-expenditure endpoints in rodent and non-human primate models.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs retatrutide naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eNo. Retatrutide is a synthetic 39-amino-acid peptide engineered with non-natural Aib substitutions for protease resistance and a C20 fatty diacid acylation for extended circulation. It does not exist in nature; its sequence is designed to engage GLP-1, GIP, and glucagon receptors simultaneously.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745388290185,"sku":null,"price":89.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":45745388322953,"sku":null,"price":489.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":45745388355721,"sku":null,"price":739.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/retatrutide-ly3437943-10mg-research-peptide_standardized.png?v=1778371040"},{"product_id":"buy-mots-c-canada","title":"MOTS-c","description":"\u003ch2\u003e\u003cb\u003eBuy MOTS-c Canada — Mitochondrial-Derived Peptide\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuy MOTS-c in Canada as a research-grade mitochondria-derived peptide for cellular bioenergetics, AMPK signaling, and mitochondrial research designs. MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA — one of only a handful of peptides known to originate from the mitochondrial genome rather than nuclear DNA. Identified in 2015 by Changhan Lee and colleagues at the USC Davis School of Gerontology, MOTS-c acts as a mitochondrial-nuclear retrograde signal that activates AMPK and shifts cellular substrate handling toward fatty acid oxidation. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₁₀₁H₁₅₂N₂₈O₂₂S₂ \/ 2174.64 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 1627580-64-6\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes MOTS-c a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eMOTS-c was identified in 2015 by Changhan Lee and colleagues in the Pinchas Cohen laboratory at the USC Davis School of Gerontology, with the original characterization published in Cell Metabolism. Its discovery extended the small but growing class of mitochondrial-derived peptides — a category that began with humanin in 2001 — and challenged the long-held view that the 12S rRNA gene region produced no functional peptides.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes MOTS-c from other research compounds is its origin. Unlike nuclear-encoded peptides translated within the cell's main protein-synthesis machinery, MOTS-c's coding sequence sits inside mitochondrial DNA, with translation occurring in the cytoplasm using the standard genetic code. The first 11 residues are highly conserved across 14 species, suggesting strong evolutionary pressure on its function. This combination — mitochondrial origin, cross-species conservation, AMPK-pathway activity — gives researchers a unique tool for probing the bioenergetic-signaling axis between mitochondria and the rest of the cell.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eInsulin Sensitivity \u0026amp; Glucose Metabolism —\u003c\/b\u003e Published animal studies have reported improved skeletal muscle glucose uptake and insulin sensitivity following MOTS-c administration, with mechanistic work attributing the effect to AMPK pathway activation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAdiposity \u0026amp; Body Composition —\u003c\/b\u003e Rodent studies of high-fat-diet-induced obesity have measured reductions in body fat mass and improved metabolic parameters in MOTS-c-treated cohorts, generating sustained interest in the peptide as a research tool for metabolic-syndrome models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eExercise Mimetic \u0026amp; Endurance —\u003c\/b\u003e MOTS-c is upregulated in response to exercise, and rodent endurance studies have reported improved running capacity and metabolic flexibility in treated animals — supporting its characterization as an endogenous exercise mimetic.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAging \u0026amp; Longevity —\u003c\/b\u003e Plasma MOTS-c levels decline with age in published human and animal data, and mid-life administration in mouse models has been examined for effects on healthspan markers, drawing interest from longevity research groups.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMitochondrial Bioenergetics —\u003c\/b\u003e As a mitochondrial-nuclear retrograde signal, MOTS-c serves as a research handle on inter-organelle communication, with studies measuring effects on substrate oxidation, mitochondrial biogenesis markers, and bioenergetic flexibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with MOTS-c often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-ss-31\" title=\"View SS-31 Product Page\"\u003eSS-31\u003c\/a\u003e\u003c\/b\u003e — Tetrapeptide that targets cardiolipin on the inner mitochondrial membrane; complements MOTS-c's signaling activity with a structural mitochondrial-stabilization mechanism, and pairs with both compounds in our Mito Stack (see below).\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/nad-plus\" title=\"View NAD+ Product Page\"\u003eNAD+\u003c\/a\u003e\u003c\/b\u003e — Mitochondrial cofactor central to sirtuin signaling and redox balance; the third compound in the Mito Stack and a frequent companion in bioenergetics research designs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/mots-c-ss31-nad-stack\" title=\"View Mito Stack Product Page\"\u003eMito Stack\u003c\/a\u003e\u003c\/b\u003e — Combined MOTS-c + SS-31 + NAD+ research blend for groups studying mitochondrial function across signaling, structural, and cofactor mechanisms in parallel.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy MOTS-c in Canada with verified purity documentation?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur MOTS-c ships to Canadian research labs and independent investigators with a batch-specific certificate of analysis confirming ≥99% HPLC purity and mass-spec identity verification. Vials are filled to approximately 104% of the labeled 10 mg as a quality margin for residual losses during reconstitution work, and ship from within Canada to avoid border-related cold-chain interruptions.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is MOTS-c different from SS-31?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eBoth are mitochondrial-focused peptides but engage entirely different mechanisms. MOTS-c is a 16-amino-acid signaling peptide encoded within mitochondrial DNA; it activates AMPK and acts as a mitochondrial-nuclear retrograde messenger. SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin on the inner mitochondrial membrane to stabilize cristae structure and reduce reactive oxygen species production. Many research designs use them together to address mitochondrial function from both signaling and structural angles.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs MOTS-c naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eYes. MOTS-c is endogenous in humans and most mammals, encoded by the MT-RNR1 gene within the mitochondrial 12S rRNA region. It is detectable in plasma in both rodents and humans, with levels that decline with age. The synthetic peptide sold for research is sequence-identical to the endogenous form.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eWhat is the evidence base for MOTS-c?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eSince the original 2015 Cell Metabolism characterization, the published literature has expanded to cover insulin sensitivity, body composition, exercise capacity, aging biomarkers, and inflammatory and host-defense functions. Animal model data are well-developed across rodent systems. Human clinical data remain limited, with most evidence drawn from preclinical work and observational studies of endogenous MOTS-c levels.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️\u003cem\u003e For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":45745410736265,"sku":null,"price":59.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":45745410769033,"sku":null,"price":319.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":45745410801801,"sku":null,"price":499.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/mots-c-10mg-peptide-canada_standardized_0761b4f8-19c9-40f5-a0fc-c60fce134492.png?v=1778370793"},{"product_id":"buy-hgh-fragment-176-191-canada","title":"HGH Fragment (176-191)","description":"\u003ch2\u003e\u003cb\u003eBuy HGH Fragment 176-191 Canada — Lipolytic hGH Peptide\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBuy HGH Fragment 176-191 in Canada as a research-grade lipolytic peptide fragment for adipose tissue research designs decoupled from the GH\/IGF-1 axis. HGH Fragment 176-191 corresponds to the C-terminal 16 amino acids of human growth hormone — the region that retains lipolytic activity but lacks the residues required for IGF-1 stimulation. Developed in the late 1990s by Frank Ng and colleagues at Monash University, the compound was subsequently advanced through Phase 2 clinical trials in obesity research under the development code AOD-9604. Each vial supplied by Emerald Peptides ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₇₈H₁₂₅N₂₃O₂₃S₂ \/ 1817.12 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 221231-10-3\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes HGH Fragment 176-191 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eHGH Fragment 176-191 was developed in the late 1990s by Frank Ng and colleagues at Monash University, Australia, as part of a structure-activity program designed to isolate the lipolytic domain of human growth hormone from its broader endocrine activity. The compound was subsequently licensed to Metabolic Pharmaceuticals — later Calzada — and advanced through Phase 2 clinical trials in obesity in the early 2000s under the development code AOD-9604.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes the fragment in research is its mechanistic specificity. Full-length hGH binds the GH receptor and triggers the complete cascade — IGF-1 elevation, growth signaling, glucose handling, and lipolysis. By using only the C-terminal 16 residues, HGH Fragment 176-191 retains lipolytic activity without engaging the GH receptor in the IGF-1-stimulating mode. That decoupling gives Canadian research groups a clean tool for studying adipose-specific hGH actions in isolation from the systemic GH\/IGF-1 axis effects that confound full-hGH study designs.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eLipolysis \u0026amp; Fatty Acid Mobilization —\u003c\/b\u003e Published preclinical studies have characterized HGH Fragment 176-191's activation of hormone-sensitive lipase and stimulation of fatty acid release from adipose tissue, with effects observed in both subcutaneous and visceral adipocyte models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAnti-Lipogenic Activity —\u003c\/b\u003e Animal studies have measured reductions in fatty acid synthesis alongside increased lipolysis, generating sustained interest in the fragment as a research tool for adipose-specific dual-mechanism investigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eBody Composition Models —\u003c\/b\u003e Rodent obesity models have reported reductions in fat mass without proportional changes in lean mass following HGH Fragment 176-191 administration, with mechanistic work attributing the selectivity to the absence of GH-receptor-mediated growth signaling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eDecoupled Metabolic Research —\u003c\/b\u003e Unlike full hGH, the fragment does not substantially elevate IGF-1 or alter glucose homeostasis in published animal models, making it a useful tool for research designs requiring lipolysis activity without confounding GH\/IGF-1 axis effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCartilage \u0026amp; Joint Research —\u003c\/b\u003e A subset of preclinical work has examined HGH Fragment 176-191 in osteoarthritis and cartilage degradation models, characterizing effects on chondrocyte signaling that are mechanistically distinct from its primary lipolytic profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with HGH Fragment 176-191 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-tesamorelin-canada\" title=\"View Tesamorelin Product Page\"\u003eTesamorelin\u003c\/a\u003e\u003c\/b\u003e — GHRH analog that stimulates pituitary GH release and triggers the full GH\/IGF-1 cascade; the standard mechanistic contrast for research designs comparing isolated lipolytic activity against full-axis activation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-retatrutide-canada\" title=\"View Retatrutide Product Page\"\u003eRetatrutide (GLP-3)\u003c\/a\u003e\u003c\/b\u003e — Triple GLP-1\/GIP\/glucagon agonist with documented adiposity-research data; provides a receptor-level metabolic-pathway contrast to HGH Fragment 176-191's adipocyte-direct lipolytic mechanism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-mots-c-canada\" title=\"View MOTS-c Product Page\"\u003eMOTS-c\u003c\/a\u003e\u003c\/b\u003e — Mitochondria-derived peptide that activates AMPK; complements HGH Fragment 176-191's lipolytic profile with a cellular-energetics angle on metabolic research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy HGH Fragment 176-191 in Canada with verified purity?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur HGH Fragment 176-191 ships to Canadian research labs and independent investigators with a batch-specific certificate of analysis confirming ≥99% HPLC purity and mass-spec identity verification. Vials are filled to approximately 104% of the labeled 10 mg as a quality margin for residual losses during reconstitution work, and ship from within Canada to avoid border-related cold-chain interruptions.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is HGH Fragment 176-191 different from Tesamorelin or full hGH?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe three operate at different points in the GH axis. Full hGH binds the GH receptor and triggers the complete cascade — IGF-1 production, growth signaling, glucose modulation, and lipolysis. Tesamorelin is a GHRH analog that stimulates pituitary GH release, indirectly producing the full hGH cascade. HGH Fragment 176-191 isolates only the C-terminal lipolytic region of hGH, retaining fat-mobilization activity without engaging the GH receptor in the IGF-1-stimulating mode. Research designs select among the three based on whether full-axis activation, indirect GH stimulation, or isolated lipolysis is the relevant mechanism.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs HGH Fragment 176-191 the same as AOD-9604?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe two are closely related and frequently treated as synonymous in research peptide markets. HGH Fragment 176-191 refers to the synthetic 16-amino-acid sequence corresponding to residues 176-191 of human growth hormone. AOD-9604 is the same fragment as developed by Metabolic Pharmaceuticals and tested in Phase 2 clinical trials in obesity. Most research suppliers use the names interchangeably, and the published preclinical literature largely treats them as equivalent compounds.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs HGH Fragment 176-191 naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePartially. The 16-amino-acid sequence corresponds exactly to residues 176-191 of native human growth hormone, an endogenous peptide hormone produced by the anterior pituitary. The fragment itself does not occur freely in nature — it is a synthetic peptide isolated from the parent hGH sequence to study the lipolytic activity of that specific region. The synthetic peptide sold for research is sequence-identical to the corresponding region of native hGH.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":46398509187209,"sku":null,"price":99.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":46398509219977,"sku":null,"price":529.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":46398509252745,"sku":null,"price":829.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/HGH-peptides-canada_35c07665-3aad-4426-b8fb-58e6a6ad45ba.png?v=1778370270"}],"url":"https:\/\/emeraldpeptides.ca\/collections\/best-peptides-for-fat-loss.oembed","provider":"Emerald Peptides","version":"1.0","type":"link"}